1 Pfizer[3] (with Wyeth[4]) U.S. 70,696 11,318 14,111 137,127
2 Johnson & Johnson U.S. 63,747 NA 10,576 119,200
3 Bayer [5] Germany 48,149 3,770 6,448 108,600
4 Hoffmann–La Roche Switzerland 43,970 NA 8,135 78,604
5 Novartis Switzerland 41,460 NA 11,946 98,200
6 Taj Pharmaceuticals Ltd. India 40,424 6,373 10,432 103,483
7 Sanofi-Aventis France 40,328 NA 7,204 99,495
8 AstraZeneca UK/Sweden 31,601 NA 5,959 67,400
9 Abbott Laboratories[6] U.S. 29,527 2,688 4,880 68,697
10 Merck & Co. U.S. 23,850 4,678 7,808 74,372
Top Pharmaceuticals Brands in India
The Indian pharmaceutical industry is the second-fastest growing industry sector in the country. It has shown a revenue growth of 27.32 per cent (as per the latest data available) to touch Rs 25,196.48 crore (Rs 251.96 billion) in 2006-07. The industry also saw Indian drug companies buying out many small firms the world over as they expand their reach, markets and muscle.
So when, Japanese drug firm Daiichi Sankyo on June 11 announced the acquisition of a majority stake of more than 50 per cent in domestic major Ranbaxy for over Rs 15,000 crore (Rs 150 billion), marking the largest ever deal in Indian pharma industry, it stunned the industry.
Ranbaxy is India's largest pharmaceutical company with a 2007 turnover of Rs 4,198.96 crore (Rs 41.989 billion) by sales. The deal will create the 15th biggest drugmaker globally.
Daiichi would also make an open offer for an additional 20 per cent stake in Ranbaxy at a price of Rs 737 per share. This deal values Ranbaxy at about $8.5 billion. Malvinder Singh will continue as CEO and MD of the Ranbaxy, post deal too.
Product | Therapeutic Category | Documentation / Specifications | CAS No. |
|---|---|---|---|
| Anti-viral drug | INN | [ 204255-11-8 ] | |
| Cough and Cold | BP / USP | [ 154-41-6 ] | |
| Cough and Cold | DMF, Cos | [ 20368-45-0 ] | |
| Etafedrine | Cough and Cold | DMF | [ 530-35-8 ] |
| Tramadol | Pain Management | TIP | [ 36282-47-0 ] |
| Methylphenidate | CNS | DMF | [ 113-45-1 ] |
| Morphine HCl | Analgesic | BP / EP | [52-26-6] |
| Morphine sulphate | Narcotic analgesic | BP / EP / USP | [64-31-3] |
| Ephedrine (EPH) | Cough and Cold | USP | [ 50-98-6 ] |
| Pseudoephedrine hydrochloride | Decongestant | INN | [ 90-82-4 ] |
| Codeine base | Analgesic,Antitussive | BP / EP / USP | [76-57-3] |
| Codeine phosphate hemihydrate | Analgesic,Antitussive | BP / EP / USP | [41444-62-6] |
| Zolpidem Tartrate | Hypnotic | BP / EP | [99294-93-6] |
Filed under: Indian Business persons, Indian Economy — battakiran @
Tags: Indian Economy, Pharma companies
Laboratory#1. Ranbaxy
The Indian pharmaceutical industry is the second-fastest growing industry sector in the country. It has shown a revenue growth of 27.32 per cent (as per the latest data available) to touch Rs 25,196.48 crore (Rs 251.96 billion) in 2006-07. The industry also saw Indian drug companies buying out many small firms the world over as they expand their reach, markets and muscle.
So when, Japanese drug firm Daiichi Sankyo on June 11 announced the acquisition of a majority stake of more than 50 per cent in domestic major Ranbaxy for over Rs 15,000 crore (Rs 150 billion), marking the largest ever deal in Indian pharma industry, it stunned the industry.
Ranbaxy is
Daiichi would also make an open offer for an additional 20 per cent stake in Ranbaxy at a price of Rs 737 per share. This deal values Ranbaxy at about $8.5 billion. Malvinder Singh will continue as CEO and MD of the Ranbaxy, post deal too.
#2. Dr Reddy’s Laboratories
Dr Reddy’s Labs, with a 2007 turnover of Rs 4,162.25 crore (Rs 41.622 billion), is
#3. Cipla
Pharma major Cipla is
#4. Sun Pharma Industries
The Dilip Sanghvi-led Sun Pharma is the nation’s 4th largest pharma company at a 2007 revenue Rs 2,463.59 crore (Rs 24.635 billion).
#5. Lupin Labs
Lupin Labs is
#6. Aurobindo Pharma
Aurobindo is
#7. GlaxoSmithKline Pharma
GSK is
#8. Cadila Healthcare
Cadila’s 2007 revenue was Rs 1,613.00 crore (Rs 16.13 billion), which makes it
#9. Aventis Pharma
Aventis Pharma, with a 2007 revenue of Rs 983.80 crore (Rs 9.838 billion) is the 9th largest Indian drug company.
#10. Ipca Laboratories
At a revenue of Rs 980.44 crore (Rs 9.804 billion), Ipca is
The leading players in the Indian pharmaceutical market comprise both India-based and MNCs. This report provides an insight to the current state of Indian pharmaceutical industry as well as the evolving trends. This report analyzes the Indian pharmaceutical industry in light of market size, key drivers and resistors, trends and competitive positioning in the global market. It also analyzes the competitive landscape of the industry based on financial and operational (field force strength, R&D spend, exposure to chronic therapeutic areas and the
This report also compares and analyzes the competitive positioning of Indian pharmaceutical market in the context of global pharmaceutical market. The report also includes profiles of the top ten companies in the industry and also involves a brief summary of top 11 to 20 players.
The top 10 companies in the Indian pharmaceutical industry were assessed on following parameters:
• market share in the Indian pharmaceutical market;
• marketed products and therapeutic focus;
• growth strategies and major acquisitions and divestments in this market;
• key partnerships and alliances formed by these companies;
• business-related strengths and weaknesses of these companies, and insights into the opportunities and threats facing them.
Key findings
The Indian pharmaceutical market was valued at $7,743m in 2008, an increase of 4.0% over 2007. Business Insights anticipates that Indian pharmaceutical market will grow at a faster pace than the global pharmaceutical market, approximately at a CAGR of 13.2% during 2009–14 to reach a total value of $15,490m in 2014.
The Indian pharmaceutical market is highly competitive and fragmented with the top 10 players accounting for 36.1% of the total R&H sales in 2008.
Use this report to
• Learn from the strategies of the Indian pharmaceutical companies to target future growth markets effectively, avoid their mistakes, replicate their successes and learn of the threats they face.
• Benchmark your performance against the leading Indian pharmaceutical companies using market share data by company and comprehending their strategies.
• Understand the major issues affecting the Indian pharmaceutical market.
• Predict the key growth areas in the Indian pharmaceuticals market arising from the change in the lifestyle of consumers and strengthening of the IPR regime in
• Save time, money and resources on analyzing the performance of the key Indian pharmaceutical companies using this report.
Key issues
Inadequacies in the new patent regime: Provisions related to Sec 3(d) of the Patent (Amendment) Act 2005 prevent ever-greening of drug patents as it does not allow patenting new uses of an existing drug. In addition, compulsory licensing allows Indian players to continue manufacturing generics of patented products for export to underdeveloped countries.
Lack of infrastructure: Problems related to frequent power cuts and lack of proper transport infrastructure will slowdown the growth of the industry.
Limited funds: Limited funding from FIs, venture capitalists and the government may slowdown the development of biotechnology industry in
Regulatory hurdles: Increasing due diligence and compliance with standards leads to cost overrunning and delay in new product launches.
Intense competition: Strong pricing competition among local manufacturers leads to low margins and limited capital to support R&D. Competition will further intensify from big generic players participating in the Indian market to leverage the cost advantage and large resource pool.
Discover
• What was the market size of the Indian pharmaceutical market in 2008?
• What will be the market size of the Indian pharmaceutical market during 2009-14?
• What are the trends in the Indian pharmaceutical market?
• Who are the top 20 players in the market?
• What is the market share of each of the top 10 companies?
• What are the growth strategies of the top 10 companies?
• What are the strengths of the top 10 players in the Indian pharmaceutical market?
• What are the growth opportunities for the global top 10 Indian pharmaceutical companies?
• What is the most contentious issue facing the Indian pharmaceutical market?
Pharmaceutical industry
From Wikipedia, the free encyclopedia
The pharmaceutical industry develops, produces, and markets drugs licensed for use as medications.[1] Pharmaceutical companies can deal in generic and/or brand medications. They are subject to a variety of laws and regulations regarding the patenting, testing and marketing of drugs.
Contents[hide] |
[edit] History
The earliest drugstores date back to the Middle Ages. The first known drugstore was opened by Arabian pharmacists in Baghdad in 754,[2] and many more soon began operating throughout the medieval Islamic world and eventually medieval Europe. By the 19th century, many of the drug stores in Europe and North America had eventually developed into larger pharmaceutical companies.
Most of today's major pharmaceutical companies were founded in the late 19th and early 20th centuries. Key discoveries of the 1920s and 1930s, such as insulin and penicillin, became mass-manufactured and distributed. Switzerland, Germany and Italy had particularly strong industries, with the UK, US, Belgium and the Netherlands following suit.
Legislation was enacted to test and approve drugs and to require appropriate labelling. Prescription and non-prescription drugs became legally distinguished from one another as the pharmaceutical industry matured. The industry got underway in earnest from the 1950s, due to the development of systematic scientific approaches, understanding of human biology (including DNA) and sophisticated manufacturing techniques.
Numerous new drugs were developed during the 1950s and mass-produced and marketed through the 1960s. These included the first oral contraceptive, "The Pill", Cortisone, blood-pressure drugs and other heart medications. MAO Inhibitors, chlorpromazine (Thorazine), Haldol (Haloperidol) and the tranquilizers ushered in the age of psychiatric medication. Valium (diazepam), discovered in 1960, was marketed from 1963 and rapidly became the most prescribed drug in history, prior to controversy over dependency and habituation.
Attempts were made to increase regulation and to limit financial links between companies and prescribing physicians, including by the relatively new U.S. Food and Drug Administration (FDA). Such calls increased in the 1960s after the thalidomide tragedy came to light, in which the use of a new tranquilizer in pregnant women caused severe birth defects. In 1964, the World Medical Association issued its Declaration of Helsinki, which set standards for clinical research and demanded that subjects give their informed consent before enrolling in an experiment. Phamaceutical companies became required to prove efficacy in clinical trials before marketing drugs.
Cancer drugs were a feature of the 1970s. From 1978, India took over as the primary center of pharmaceutical production without patent protection.[citation needed]
The industry remained relatively small scale until the 1970s when it began to expand at a greater rate.[citation needed] Legislation allowing for strong patents, to cover both the process of manufacture and the specific products, came in to force in most countries. By the mid-1980s, small biotechnology firms were struggling for survival, which led to the formation of mutually beneficial partnerships with large pharmaceutical companies and a host of corporate buyouts of the smaller firms. Pharmaceutical manufacturing became concentrated, with a few large companies holding a dominant position throughout the world and with a few companies producing medicines within each country.
The pharmaceutical industry entered the 1980s pressured by economics and a host of new regulations, both safety and environmental, but also transformed by new DNA chemistries and new technologies for analysis and computation.[citation needed] Drugs for heart disease and for AIDS were a feature of the 1980s, involving challenges to regulatory bodies and a faster approval process.
Managed care and Health maintenance organizations (HMOs) spread during the 1980s as part of an effort to contain rising medical costs, and the development of preventative and maintenance medications became more important. A new business atmosphere became institutionalized in the 1990s, characterized by mergers and takeovers, and by a dramatic increase in the use of contract research organizations for clinical development and even for basic R&D. The pharmaceutical industry confronted a new business climate and new regulations, born in part from dealing with world market forces and protests by activists in developing countries. Animal Rights activism was also a problem.
Marketing changed dramatically in the 1990s, partly because of a new consumerism.[citation needed] The Internet made possible the direct purchase of medicines by drug consumers and of raw materials by drug producers, transforming the nature of business. In the US, Direct-to-consumer advertising proliferated on radio and TV because of new FDA regulations in 1997 that liberalized requirements for the presentation of risks. The new antidepressants, the SSRIs, notably Fluoxetine (Prozac), rapidly became bestsellers and marketed for additional disorders.
Drug development progressed from a hit-and-miss approach to rational drug discovery in both laboratory design and natural-product surveys. Demand for nutritional supplements and so-called alternative medicines created new opportunities and increased competition in the industry. Controversies emerged around adverse effects, notably regarding Vioxx in the US, and marketing tactics. Pharmaceutical companies became increasingly accused of disease mongering or over-medicalizing personal or social problems.[3]
The leading players in the Indian pharmaceutical market comprise both India-based and MNCs. This report provides an insight to the current state of Indian pharmaceutical industry as well as the evolving trends. This report analyzes the Indian pharmaceutical industry in light of market size, key drivers and resistors, trends and competitive positioning in the global market. It also analyzes the competitive landscape of the industry based on financial and operational (field force strength, R&D spend, exposure to chronic therapeutic areas and the US pharmaceutical market) parameters.
This report also compares and analyzes the competitive positioning of Indian pharmaceutical market in the context of global pharmaceutical market. The report also includes profiles of the top ten companies in the industry and also involves a brief summary of top 11 to 20 players.
The top 10 companies in the Indian pharmaceutical industry were assessed on following parameters:
• market share in the Indian pharmaceutical market;
• marketed products and therapeutic focus;
• growth strategies and major acquisitions and divestments in this market;
• key partnerships and alliances formed by these companies;
• business-related strengths and weaknesses of these companies, and insights into the opportunities and threats facing them.
